Literature DB >> 3718539

Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N.

I A Sheikh, A P Kaplan.   

Abstract

We have compared the digestion of bradykinin, lysyl bradykinin, and kinin degradation products by carboxypeptidases N, B and A (CPN, CPB and CPA). Carboxypeptidase N removed the C-terminal arginine from bradykinin or lysyl bradykinin to leave the des-Arg derivative of each, and no further degradation occurred regardless of enzyme concentration or time of incubation. However, both CPB and CPA degraded the des-Arg derivatives to remove the C-terminal phenylalanine. The inhibitory effect of phosphate ions upon this activity of CPB (but not CPA) suggests that CPA may be responsible for the formation of free phenylalanine seen upon degradation of kinins in plasma or serum. However, angiotensin converting enzyme degraded des-Arg9-bradykinin in plasma or serum prior to such Phe removal to yield the pentapeptide Arg-Pro-Pro-Gly-Phe and the tripeptide Ser-Pro-Phe. We demonstrated that CPB degraded Arg-Pro-Pro-Gly-Phe but not Ser-Pro-Phe; this reaction was also inhibited by phosphate ions. Carboxypeptidase A, on the other hand, liberated Phe from both peptides in phosphate-buffered saline and accounted, at least in part, for the free phenylalanine detected. Carboxypeptidase N did not digest the aforementioned pentapeptide or tripeptide. It is clear that carboxypeptidase B and carboxypeptidase A had overlapping activities, depending upon the substrate tested, and were distinguished by the effects of different ionic environments. We further suggest a role for carboxypeptidases other than CPN in the degradation of kinins in human plasma or serum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718539     DOI: 10.1016/0006-2952(86)90727-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

Review 1.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  Cross-talk between the complement and the kinin system in vascular permeability.

Authors:  Fleur Bossi; Ellinor I Peerschke; Berhane Ghebrehiwet; Francesco Tedesco
Journal:  Immunol Lett       Date:  2011-07-06       Impact factor: 3.685

3.  Metabolism of bradykinin and angiotensin I by human basilar artery and rabbit aorta.

Authors:  E T Whalley
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

Review 4.  Localization and regulation of the renal kallikrein kinin system: possible relations to renal transport functions.

Authors:  W G Guder; J Hallbach
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 5.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

6.  Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC.

Authors:  Y Matsumura; H Maeda; H Kato
Journal:  Agents Actions       Date:  1990-03

Review 7.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.

Authors:  J R Snyman; D K Sommers
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

9.  The contribution of gC1qR/p33 in infection and inflammation.

Authors:  Ellinor I B Peerschke; Berhane Ghebrehiwet
Journal:  Immunobiology       Date:  2007-01-03       Impact factor: 3.144

10.  Effects of the bradykinin antagonist B4310 on smooth muscles and blood pressure in the rat, and its enzymatic degradation.

Authors:  T Griesbacher; F Lembeck; A Saria
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.